Andrew Meds review
A clean product page with a published price, in front of intake funnels that quote different numbers and sell a different program.
Pricing last checked on Andrew Meds's own site .
- Semaglutide
- $199/mo (product-page rate; the intake funnels quote different figures, compounded)
- Tirzepatide
- $299/mo (product-page rate; no funnel reached today offered it, compounded)
- Coverage
- All 50 states
- Brand-name
- Compounded only
The scorecard
Andrew Meds scored on our six published factors. See the methodology.
What we like
- The compounding class is disclosed on the product pages themselves, written as 503(A) or 503(B) rather than left to the reader to guess
- The prescribing practice is named in the footer of every page, with its own address, phone number and support address
- Unusually, the Terms tell you outright that you may fill the prescription at any pharmacy of your choice
- A toll-free number and a support address are published, and the account carries a self-serve cancellation control
- Both molecules are listed at labeled weekly doses, with a microdose tier alongside
The caveats
- Three semaglutide prices are live at once — the product page, the microdosing funnel and a four-week supply in a second funnel — and no page reconciles them
- Every Get Started button on the semaglutide product page lands on a microdosing funnel, and the word microdosing appears nowhere on the marketing site
- Both GLP-1 intakes ended by offering semaglutide only, so whether tirzepatide can actually be bought through the current funnels is unresolved
- One funnel's plan ladder does not add up: its stated savings only reconcile if the per-month figures are read as totals, which the page never says
- No pharmacy is named, no individual clinician is named, no NPI is published, and support hours are stated nowhere
The verdict
Best for: A reader with time to reconcile three figures, because the price you are shown depends on which door you walk through. A clean product page with a published price, in front of intake funnels that quote different numbers and sell a different program.
Ranked #152 of 539 providers we have reviewed — for comparison, read the CoreAge Rx review, our #1 pick. In the ranking it sits between SnagRx at #151, 68/100 above and Lean Meds at #153, 70/100 below, with the Mondae ruling the next one down.
If that ruling leaves you undecided, the 7 programs we rank against Andrew Meds are graded on the same six factors and listed in score order.This ruling sits inside a bigger one: the complete ranking puts this ruling in context against every program we track. We have also ruled on it directly: CoreAge Rx vs Andrew Meds goes to CoreAge Rx, 94/100 to 70/100.
Compare with other providers
The closest rulings to Andrew Meds by Verdict Score — the realistic shortlist if you are weighing this one up.
- #145TeleHealth Weight Solutions— TeleHealth Weight Solutions (branded Medi Health Clinics) is a nurse-practitioner-managed telehealth program prescribing compounded semaglutide and tirzepatide for weight loss, shipped with supplies from…71/100
- #146Tru2u— Tru2u is a US direct-to-consumer telehealth and wellness store offering provider-guided compounded GLP-1 weight-loss therapy alongside hair, skincare, and supplement lines.71/100
- #147Voxy— Voxy is a Scottsdale, Arizona telehealth practice offering compounded semaglutide and tirzepatide alongside NAD+ and sermorelin.71/100
- #148Oak— One price at every dose and no subscription to cancel — but Oak publishes nine different "starting" prices, attaches a billing term to none of them, and will not name a rate until you have finished a 29-question intake.68/100
- #149MyDrHank— A six-shelf prescription telehealth catalog that publishes its whole GLP-1 term ladder up front — and then advertises only the twelve-month prepay rung, so the price you see is never the price you pay monthly.68/100
- #150SkinnyRx— Sells compounded tirzepatide as a tablet at the same price as the injection, which few rows here do — but its headline rate is the twelve-month rung, charged as a single up-front payment, and the company carries an FDA warning letter from February 2026.68/100
Pricing, states and verification reflect Andrew Meds's public disclosures at last review; the Verdict Score is our editorial judgment per the methodology. Prices change — confirm on Andrew Meds's site. Not medical advice; see our disclosure.